Screener
Danaher DHR Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Sales by Business | ||||||
| Biotechnology | $1.92B+3.8% | $1.8B+11.5% | $2.03B+8.8% | $1.8B+8.8% | $1.85B+8.0% | |
| Diagnostics | $2.47B+6.8% | $2.42B-1.3% | $2.72B+3.1% | $2.46B+4.2% | $2.31B+2.2% | |
| Life Sciences | $1.88B+5.7% | $1.74B+3.4% | $2.09B+2.6% | $1.79B+0.6% | $1.78B+0.4% | |
| Sales by Product | ||||||
| Nonrecurring revenue | $1.07B+10.2% | $920M-0.5% | $1.51B+5.7% | $1.04B+1.5% | $966M-8.3% | |
| Recurring revenue | $5.2B+4.6% | $5.03B+4.5% | $5.32B+4.3% | $5.02B+5.0% | $4.97B+6.0% | |
| Sales by Geography | ||||||
| High-growth markets | $1.96B+15.4% | $1.62B+5.7% | $2.03B+5.9% | $1.76B+2.2% | $1.7B+0.1% | |
| North America | $2.47B+1.5% | $2.48B-4.0% | $2.76B-0.6% | $2.58B+5.0% | $2.44B+0.2% | |
| Other developed markets | $293M-0.3% | $284M+2.2% | $364M+1.4% | $316M+5.7% | $294M+0.7% | |
| Western Europe | $1.54B+2.2% | $1.57B+16.4% | $1.69B+13.3% | $1.4B+5.8% | $1.51B+14.1% |
FAQ
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
